Glaxosmithkline Intellectual Property Development Limited

Chinese Academy of Sciences

Yang Zhan

Feng Ren

Weiqiang Xing

Baowei Zhao

Yingxia Sang

Xiao Ding

Zehong Wan

Fajun Nan

Ying Xiong

Qian Liu

Xiaowei Zhang

Yangming Zhang

Hailong Wang

Yun Jin

Luigi Piero Stasi

Boliang Li

Xichan Hu

Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved. 

Compounds for inhibiting LRRK2 kinase activity

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

The present invention relates to a series of analogs of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogs of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like. 

Tricyclic analogues, preparation method and uses thereof

Growing community of inventors

Shanghai, China

Yang Zhan